| pubmed-article:18579806 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18579806 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:18579806 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:18579806 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:18579806 | lifeskim:mentions | umls-concept:C0684224 | lld:lifeskim |
| pubmed-article:18579806 | lifeskim:mentions | umls-concept:C0205265 | lld:lifeskim |
| pubmed-article:18579806 | lifeskim:mentions | umls-concept:C0205088 | lld:lifeskim |
| pubmed-article:18579806 | lifeskim:mentions | umls-concept:C1555582 | lld:lifeskim |
| pubmed-article:18579806 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:18579806 | pubmed:dateCreated | 2008-8-12 | lld:pubmed |
| pubmed-article:18579806 | pubmed:abstractText | Ten-year follow-up results from the Parkinson's Disease Research Group of the United Kingdom trial demonstrated that there were no long-term advantages to initiating treatment with bromocriptine compared with l-dopa in early Parkinson disease (PD). Increased mortality in patients on selegiline combined with l-dopa led to premature termination of this arm after 6 years. | lld:pubmed |
| pubmed-article:18579806 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18579806 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18579806 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18579806 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18579806 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:18579806 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18579806 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18579806 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18579806 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18579806 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18579806 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:18579806 | pubmed:issn | 1526-632X | lld:pubmed |
| pubmed-article:18579806 | pubmed:author | pubmed-author:LeesA JAJ | lld:pubmed |
| pubmed-article:18579806 | pubmed:author | pubmed-author:EvansAA | lld:pubmed |
| pubmed-article:18579806 | pubmed:author | pubmed-author:HeadJJ | lld:pubmed |
| pubmed-article:18579806 | pubmed:author | pubmed-author:Ben-ShlomoYY | lld:pubmed |
| pubmed-article:18579806 | pubmed:author | pubmed-author:Katzenschlage... | lld:pubmed |
| pubmed-article:18579806 | pubmed:author | pubmed-author:SchragAA | lld:pubmed |
| pubmed-article:18579806 | pubmed:author | pubmed-author:Parkinson's... | lld:pubmed |
| pubmed-article:18579806 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18579806 | pubmed:day | 12 | lld:pubmed |
| pubmed-article:18579806 | pubmed:volume | 71 | lld:pubmed |
| pubmed-article:18579806 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18579806 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18579806 | pubmed:pagination | 474-80 | lld:pubmed |
| pubmed-article:18579806 | pubmed:dateRevised | 2009-3-3 | lld:pubmed |
| pubmed-article:18579806 | pubmed:meshHeading | pubmed-meshheading:18579806... | lld:pubmed |
| pubmed-article:18579806 | pubmed:meshHeading | pubmed-meshheading:18579806... | lld:pubmed |
| pubmed-article:18579806 | pubmed:meshHeading | pubmed-meshheading:18579806... | lld:pubmed |
| pubmed-article:18579806 | pubmed:meshHeading | pubmed-meshheading:18579806... | lld:pubmed |
| pubmed-article:18579806 | pubmed:meshHeading | pubmed-meshheading:18579806... | lld:pubmed |
| pubmed-article:18579806 | pubmed:meshHeading | pubmed-meshheading:18579806... | lld:pubmed |
| pubmed-article:18579806 | pubmed:meshHeading | pubmed-meshheading:18579806... | lld:pubmed |
| pubmed-article:18579806 | pubmed:meshHeading | pubmed-meshheading:18579806... | lld:pubmed |
| pubmed-article:18579806 | pubmed:meshHeading | pubmed-meshheading:18579806... | lld:pubmed |
| pubmed-article:18579806 | pubmed:meshHeading | pubmed-meshheading:18579806... | lld:pubmed |
| pubmed-article:18579806 | pubmed:meshHeading | pubmed-meshheading:18579806... | lld:pubmed |
| pubmed-article:18579806 | pubmed:meshHeading | pubmed-meshheading:18579806... | lld:pubmed |
| pubmed-article:18579806 | pubmed:meshHeading | pubmed-meshheading:18579806... | lld:pubmed |
| pubmed-article:18579806 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18579806 | pubmed:articleTitle | Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. | lld:pubmed |
| pubmed-article:18579806 | pubmed:affiliation | National Hospital for Neurology and Neurosurgery, Queen Square, London, UK. | lld:pubmed |
| pubmed-article:18579806 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18579806 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:18579806 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:18579806 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18579806 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18579806 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18579806 | lld:pubmed |
